Author:

Keywords:

AIRWAY, AMPHIREGULIN, EXPRESSION, IL-33 PROMOTES, Immunology, INNATE LYMPHOID-CELLS, Life Sciences & Biomedicine, METABOLISM, PHOSPHATASE, PLASTICITY, Science & Technology, SEVERE ASTHMA, TRAFFICKING, Adolescent, Adult, Aged, Asthma, Drug Resistance, Female, Glucocorticoids, Humans, Immunity, Innate, Leukocyte Common Antigens, Lymphocytes, Male, Middle Aged, Nasal Polyps, Severity of Illness Index, Young Adult, 3202 Clinical sciences, 3204 Immunology

Abstract:

Group 2 innate lymphoid cells (ILC2s) orchestrate protective type 2 immunity and have been implicated in various immune disorders. In the mouse, circulatory inflammatory ILC2s (iILC2s) were identified as a major source of type 2 cytokines. The human equivalent of the iILC2 subset remains unknown. Here, we identify a human inflammatory ILC2 population that resides in inflamed mucosal tissue and is specifically marked by surface CD45RO expression. CD45RO+ ILC2s are derived from resting CD45RA+ ILC2s upon activation by epithelial alarmins such as IL-33 and TSLP, which is tightly linked to STAT5 activation and up-regulation of the IRF4/BATF transcription factors. Transcriptome analysis reveals marked similarities between human CD45RO+ ILC2s and mouse iILC2s. Frequencies of CD45RO+ inflammatory ILC2 are increased in inflamed mucosal tissue and in the circulation of patients with chronic rhinosinusitis or asthma, correlating with disease severity and resistance to corticosteroid therapy. CD45RA-to-CD45RO ILC2 conversion is suppressed by corticosteroids via induction of differentiation toward an immunomodulatory ILC2 phenotype characterized by low type 2 cytokine and high amphiregulin expression. Once converted, however, CD45RO+ ILC2s are resistant to corticosteroids, which is associated with metabolic reprogramming resulting in the activation of detoxification pathways. Our combined data identify CD45RO+ inflammatory ILC2s as a human analog of mouse iILC2s linked to severe type 2 inflammatory disease and therapy resistance.